In this first Pointellis episode, Adlai Goldberg speaks with Asaf Adler, Operations Senior Manager with EY, about his emotional journey from stage 4 melanoma to full remission.

Asaf Adler, EY Americas Senior Manager for Consulting, Business Consulting, Supply Chain & Operations, faced among the hardest patient challenges imaginable: stage 4 melanoma and lung cancer. But, today, as a cancer survivor, he’s optimistic about the state of cancer treatments. In this podcast, Adlai Goldberg, EY Social and Commercial Innovation Life Sciences Leader, speaks with Asaf about his experience finding out he had cancer to his discovery of individual-targeted treatments, his journey to remission and overall advancements in the life science sector.

Summer 2021 is a milestone in cancer treatment, as Phase 2 of the mRNA cancer vaccine (BioNTech) is introduced to its first patient. Asaf and Adlai share their excitement and hope around this amazing era of hope for cancer treatment.

Asaf’s own remarkable story underscores how quickly the clinical science is advancing and the profound impact these treatments have not only on the lives of current patients, but also to the loved ones surrounding them.

In this first episode of our EY Health Sciences and Wellness Experience podcast series, we explore the emerging and much needed age of "Health Experience" and the disruptive health innovation emerging in the aftermath of the covid 19 pandemic. The Covid 19 impact on healthcare was immense and Health Sciences and Wellness industry has never been as "front and centre" in our lives as it has been in this last year. As all of us, worldwide, ride the various waves of the pandemic, our Health Sciences and Wellness industry has taken the lead in healthcare analytics and healthcare innovation and giving care to those who have needed it most. We have also seen a monumental collaborative R&D effort – at a scale never witnessed before. Tune in as we explore the various trends in healthcare innovation, technology and analytics that are reshaping the Health Sciences and Wellness Industry and driving the evolution of the smart health systems of the future that can deliver an improved Health Experience.

The COVID-19 pandemic provides the ‘burning platform’ for accelerating the data agenda. While companies and organizations long recognized the potential of new tools to capture and use data to transform health, they lacked the “burning platform” to fuel this change. The COVID-19 pandemic and the global disruption it caused has demonstrated that organizations can become more resilient, agile and innovative if they shift to digitally enabled business models with data at the core.

New technologies are creating new opportunities, but they are also creating unknown and unquantified risks. Organizations that understand what it takes to succeed with new cost and revenue models, new value propositions, and new relationships with the right partners, will start to reshape the health market. In this edition of New Horizons, we explore four areas where this process of reshaping is underway.

With dealmaking a cornerstone of the growth strategy, 2020 will be a robust year for life sciences M&A. To succeed, companies must continue to focus their business models, close near term growth gaps and invest in future innovation.

In the EY 2019 Pulse of the industry, we review the performance of the global medical technology industry. The industry continues to grow, but its long-term outlook is at risk from underinvestment in R&D and lack of collaboration between industry providers, payers and patients.

Nothing can change if minds do not. How can we make common ground the foundation for real change? As technology increasingly takes on the role of management, more emphasis falls on the role of leaders. Neuroscience is uncovering approaches to influence that leaders can use to enlist others to share their beliefs and commitments.

Five trends are leading the rise of a new, data-centric approach to health care. An organization’s ability to generate value depends on how effectively it can unlock the power of data and generate insights by connecting, combining and securely sharing data at greater scale than ever before. Learn more by visiting us at ey.com/lifesciences

Over the past three decades, life sciences companies have used their biological and chemical know-how to create significant value for themselves, their shareholders and most importantly patients. In today’s fast-changing environment, it’s very likely that life sciences companies will need access to an array of medical and non-medical data to demonstrate value to their stakeholders.

An EY study shows that data and digital are transforming the life sciences industry. Hear from leaders how industry players can seize the upside of this disruption, and what it means for patient-consumers.